Product image of Linagliptin/Metformin Hexal (Metformin Hydrochloride, Linagliptin) supplied by GNH India

Linagliptin/Metformin Hexal

Active Ingredient:
Metformin Hydrochloride, Linagliptin
Origin:
EU

Linagliptin/Metformin Hexal (Metformin Hydrochloride, Linagliptin)

Linagliptin, the active ingredient in Linagliptin/Metformin Hexal, is a DPP‑4 inhibitor presented as an oral tablet for oral use. It helps control blood glucose in adults with type 2 diabetes when used with diet and exercise. Metformin hydrochloride, also present, is a biguanide that reduces hepatic glucose production and improves insulin sensitivity.

GNH India supplies Linagliptin/Metformin Hexal as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Hexal Ag

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Linagliptin/Metformin Hexal is indicated for the management of type 2 diabetes mellitus, acting on glucose metabolism pathways.

  • Type 2 diabetes mellitus: improves overall glycaemic control when combined with diet and exercise.
  • Inadequate control on metformin alone: adds DPP‑4 inhibition to further lower HbA1c.
  • Adjunct to other oral antidiabetics: can be combined with sulfonylureas or insulin for additional glucose lowering.

How It Works

  • Linagliptin selectively inhibits dipeptidyl peptidase‑4 (DPP‑4), raising endogenous incretin levels and enhancing glucose‑dependent insulin secretion while reducing glucagon release. Metformin hydrochloride decreases hepatic gluconeogenesis, lowers intestinal glucose absorption, and improves peripheral insulin sensitivity, together producing a complementary reduction in blood glucose.

Side Effects

Adverse reactions may occur with Linagliptin/Metformin Hexal and are categorized by frequency.

Common Side Effects

  • Nausea: mild to moderate gastrointestinal upset.
  • Diarrhoea: loose stools, usually transient.
  • Headache: mild tension‑type headache.
  • Dizziness: occasional light‑headedness.

Serious or Rare Side Effects

  • Lactic acidosis: rare but life‑threatening metabolic complication.
  • Pancreatitis: severe abdominal pain with elevated enzymes.
  • Severe allergic reactions: rash, angioedema, or anaphylaxis.
  • Hepatic dysfunction: abnormal liver enzymes or hepatitis.

Precautions & Warnings

Before prescribing Linagliptin/Metformin Hexal, clinicians should consider several safety aspects.

  • Renal function assessment: evaluate eGFR, especially for metformin component.
  • Hepatic impairment: use with caution in patients with liver disease.
  • Risk of lactic acidosis: avoid in patients with conditions predisposing to hypoxia.
  • Pregnancy and lactation: safety not established; use only if benefits outweigh risks.
  • Drug interaction monitoring: review concomitant medications that affect glucose or renal clearance.
  • Store at ambient temperature: keep in original packaging, protect from moisture and heat.

Avoid Interactions

Linagliptin/Metformin Hexal may interact with other medicines; interactions are grouped by clinical relevance.

Major Interactions (Avoid)

  • Iodinated contrast agents: may precipitate metformin‑associated lactic acidosis; discontinue metformin before imaging.
  • Insulin secretagogues (e.g., sulfonylureas): increase risk of severe hypoglycaemia.
  • Rifampin: reduces linagliptin exposure, diminishing efficacy.

Moderate Interactions (Monitor Closely)

  • Beta‑blockers: can mask hypoglycaemia symptoms.
  • NSAIDs or diuretics: may impair renal function, affecting metformin clearance.
  • ACE inhibitors or ARBs: monitor renal function and electrolytes when combined.

Frequently Asked Questions

Linagliptin/Metformin Hexal is an oral antidiabetic medication indicated for the treatment of type 2 diabetes mellitus in adults. It combines a DPP‑4 inhibitor with a biguanide to improve blood‑glucose control when used alongside diet and exercise.

Linagliptin blocks the enzyme dipeptidyl peptidase‑4, which increases levels of incretin hormones. This enhances glucose‑dependent insulin secretion and reduces glucagon release, helping lower blood glucose levels.

The specific dose and dosing schedule are determined by the prescribing clinician based on the patient’s clinical condition, renal function, and response to therapy. Patients should follow the prescriber’s instructions exactly.

Safety in pregnancy and lactation has not been established. The medication should only be used if the potential benefit justifies the possible risk to the fetus or infant, and this decision must be made by a qualified health professional.

To place an order, submit an enquiry on the product page at gnhindia.com indicating the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with sulfonylureas, the Linagliptin/Metformin combination offers a lower risk of hypoglycaemia and does not cause weight gain. Unlike SGLT2 inhibitors, it does not increase urinary glucose excretion, but it shares the benefit of improving glycaemic control without insulin.

Store the tablets at ambient temperature, below 25 °C, in the original container to protect from moisture and light. Keep out of reach of children and do not use after the expiry date printed on the package.

The medication is taken orally, usually with meals to reduce gastrointestinal discomfort. Tablets should be swallowed whole with a glass of water and not crushed or chewed unless specifically instructed by a healthcare provider.

Serious risks include lactic acidosis (particularly in patients with renal impairment), pancreatitis, severe allergic reactions such as anaphylaxis, and hepatic dysfunction. Patients should be educated to seek immediate medical attention if they experience symptoms suggestive of these conditions.

The combination should be avoided in patients with severe renal impairment (eGFR < 30 mL/min/1.73 m²), known hypersensitivity to either component, or a history of lactic acidosis. It is also contraindicated in individuals with acute or chronic metabolic acidosis.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Metformin Hydrochloride, Linagliptin

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT